

Meeting of the 134th Meeting of the IFCC Executive Board, February 17-19, 2018

Minutes

The 134th Meeting of the IFCC Executive Board was held at the IFCC Office, Milan.

Participants:

EB Members

Howard Morris	(HM)	President
Maurizio Ferrari	(MF)	Past-President
David Kinniburgh	(DK)	Secretary
Tomris Ozben	(TO)	Treasurer
Rolf Hinzmann	(RH)	Corporates Representative (Roche)

IFCC Regional Federation Representatives

Adekunle Bashiru Okesina	(ABO)	African Federation of Clinical Chemistry (AFCC)
Abderrazek Hedhili	(AH)	Arab Federation of Clinical Biology (AFCB)
Sunil Sethi	(SSE)	Asia-Pacific Fed for Clinical Biochemistry and Lab Med (APFCB)
Sverre Sandberg	(SSA)	European Fed of Clin Chem and Lab Med (EFLM)
Rosa Sierra-Amor	(RSA)	Latin-American Conf of Clin Biochemistry (COLABIOCLI)
Ann Gronowski	(AG)	North American Fed of Clin Chem and Lab Med (NAFCC)

1.0 Opening remarks from President

President Howard Morris welcomed everyone to the first meeting of the new 2018-2020 EB and the first meeting in the new EB format with Regional Federation representation. HM reviewed his vision of the new EB and the important role of the Regional Federation representatives to improve the two way communication and cooperation between the IFCC and the Regional National Members. Clarification of the relationship between the Federations and the IFCC will be part of the new EB Strategic Plan.

2020 EB Election

In 2020 Council meeting will be in May and elections must be over by then. The new process will be compressed with election for President Elect starting in March and ending in October. The election for the Treasure and Secretary will start in July and will end in January. The election for the Regional Federation Representatives and the Corporate Representative will start in September and will end in Mach. Application forms will be standardized. It was also noted that the National Members should be encouraged to nominate a slate of candidates with greater female, age and geographic mix.

Strategic Planning Session, Saturday, 17 February 17, 2008

The EB developed the following draft Strategic Plan for the IFCC Executive Board for the three year period 2018-2020, inclusive. Strategic actions are identified and classified into the following four broad areas:

Strategic Plan from 134th EB Meeting:

Area A: Supporting our Membership

No.	Strategic Action	
1	<ul style="list-style-type: none"> a) Vertical integration of educational programs b) Continue to publicize educational resources available from IFCC c) Work with National Members and Federations to make better use of the educational resources available from IFCC d) Continue to promote 2 way communication with National Members and Federations and coordinate activities. e) Continue to develop and present a series of webinars to meet the needs of Members. 	<p>HM / CPD HM / CPD</p> <p>EB, Reg Fed Reps, NS representatives</p> <p>EB, Reg Fed Reps, NS representatives</p> <p>HM / CPD</p>
2	<ul style="list-style-type: none"> a) Maintain and improve communication with COLABIOCLI and Members in Latin America, as required. b) Maintain and improve communication with AFCB and Members in Arab countries, as required. c) Maintain and improve communication with AFCC and Members in African countries, as required. d) Maintain and improve communication with EFLM and Members in the European countries, as required. e) Maintain and improve communication with APFCB and Members in the Asia-Pacific countries, as required. f) Maintain and improve communication with NAFCC and Members in the North American countries, as required. 	<p>RSA / COLABIOCLI</p> <p>AH / AFCB</p> <p>AO / AFCC</p> <p>SSA / EFLM</p> <p>SSE / APFCB</p> <p>AG / NAFCC.</p>
3	Conduct a survey of age, sex, geography and corporate membership for all IFCC functional groups, and develop a plan to address any disparities.	DK / CPD
4	Establish a Working Group made up of Corporate Members to identify and prioritize their needs, and possible projects, along with recommended membership. Assign to appropriate Division.	HM / RH / Corp Mem reps within Divisions/ Divisional Exec Cttee's EC
5	Promote to Corporate Members the use of the IFCC Registry of Experts.	RH / Corp Mem reps within Divisions

Area B: Broadening Our Horizons

No	Strategic Action	
6	To translate the principles of metrology to one new project each year in areas of laboratory medicine other than clinical chemistry.	HM / P Gillery, SD
7	<p>Establish at least one new collaboration each year with an international clinical organisation.</p> <p>An international scientific association, the European Society for Clinical Cell Analysis (ESCCA, President Anna Konstanti), is interested to join IFCC.</p>	
8	Invite organisations from outside laboratory medicine to contribute to the IFCC meetings to promote better interaction with healthcare professionals. Project based.	HM / RH

9	Reach out to LIS vendors to collaborate on symposia presentations and development guidelines and standards of practice. Identify possible projects to standardize and harmonize post analytical LIS processes. Encourage IFCC Corporate membership.	SSE / Robert Flatman
10	Explore the use of electronic meetings by IFCC functional groups. CPD to into this.	HM / CPD
11	Explore the potential evolution of congress format to include electronic participation.	HM, JW, C-CC

Area C: Improving the Quality of Laboratory Medicine

No.	Strategic Action	
12	In conjunction with others develop a route to laboratory accreditation for developing countries	HM / EMD, DQCLM / ASLM
13	Identify the objectives with respect to a media campaign to promote the IFCC and the value of lab medicine.	DK / CPD
14	Strengthen the links and collaboration with the World Health Organization (WHO)	HM / PG, SD

Area D: Improving the Effectiveness of IFCC

No.	Strategic Action	
15	Performance evaluation of functional units including EB	
16	Develop a new fee structure and implementation plan for Affiliate members	MF, TO

The strategic plan will be finalized at the EB meeting in Rome in July.

Normal Business Meeting, Sunday, 18 February and Monday, 19 February, 2018

1.0 Preliminaries

1.1.133 Minutes of 133rd EB Meeting, Durban, South Africa October, 2017

The EB previously approved the Full Minutes and the Summary Minutes from the 133rd Meeting. All business arising from the 133rd EB Meeting was included in the agenda items for the 134th EB Meeting.

2.0 Full Member Societies

2.2 Applications for Full Membership

No new applications were received.

2.3 Withdrawal – Suspended Members

The Honduras Society was suspended at the end of 2017 and would like to return. The Head Office will investigate.

2.4 Annual Dues for Full Members

The EB is contacting those members who are behind in their dues.

3.0 Corporate Members

RH provided the following report:

Since the last General Council Meeting (3 years ago) 4 companies joined IFCC while 13 left. 3 other companies have announced to terminate their membership end of 2017. As of January 2018, IFCC had 43 Corporate Members. (In 2017 the IFCC was pleased to welcome *Beijing Dream Diagnostic Medicine* as a new Corporate Member and *Hemas Hospitals Sri Lanka* joined at the beginning of 2018. Regrettably seven companies left IFCC in 2017: *Response Biomedical*, *Sonic Healthcare Europe*, *Philips*, *Axis Shield*, *Unilabs*, *Elga Labwater* and *Instrumentation Laboratory*.)

The perception of many Corporate Members is that the major benefit for Corporate Members in IFCC is the discount at exhibition rates and this does not encourage to continue membership for those who do not exhibit. It is relevant to discuss how IFCC can be more attractive for Corporate Members. Although this topic has been discussed several times and despite several suggestions

from the side of the Corporate Members no real progress has been made over the past 3 years. The loss of Corporate Members puts a financial threat on IFCC.

Interest in new IFCC membership comes mainly from China and Eastern Europe, not from manufacturers but from distributors who want to reach out for the world-wide IVD market, and there is sporadic interest from large labs. IFCC needs to discuss the impact of this development and assure that the organization still serves the interest of its traditional members, i.e. IVD manufacturers, who will become a minority if this trend continues.

New rules of the MedTech Europe code took effect in January 2018: Direct sponsorship of speakers and delegates at conferences by the industry is no longer permitted. Companies are not so much in favour of indirect sponsorship and are more confident in organizing their own educational symposia, including new ways of scientific communication such as webinars. The industry has the opinion that medical education is important, however, there are several topics that need to be discussed:

1. Do we need all conferences? If not, what are the priorities?
2. Will company exhibitions / satellite symposia still play a major role when the number of conference delegates is declining?
3. How to make sure that conferences are priced appropriately and that the perceived value is so large that sufficient delegates choose to pay by themselves? Can overhead cost / non-education-related cost be reduced?
4. How to make sure that education reaches the appropriate target group and that delegates attend most of the lectures during the conference?
5. Conferences do not only have an educational aspect but also constitute a business model (substantial source of income) for IFCC. This adds to the cost. Does the business model have to be adapted?

EuroMedLab in Athens: IFCC successfully sold all exhibition space at EuroMedLab; however, the distribution of the exhibition over several floors was not optimal for many of the exhibiting companies, particularly those on the upper floors complained that they had almost no visitors at all. Those responsible to organize future events need to work on means to prevent this for upcoming conferences. Manufacturers not only miss visitors at the exhibition but they want to avoid any implicit allegations that manufacturers are sponsoring tourism.

IFCC WoldLab 2017 in Durban: The conference attracted less visitors than industry had expected. The exhibition area had to be reduced substantially due to lack of interest from exhibiting companies.

RH reported that there is an opportunity for IFCC to collaborate with EASD, the largest diabetes conference in Europe. The IFCC has the opportunity to sponsor 2 speakers at the Berlin meeting in October 2018. RH to contact the 2 prospective speakers for the EASD meeting and indicate IFCC willingness support this, which should come from the functional group budget.

HM summarized the 3 items from the Strat Plan that relate to Corporate Members (#4, #5 and #9) RH will consider and suggest a Corporate representative to chair this group. Once in place this group will need Terms of Reference and a clear relationship with the other functional groups. The Corporate Members should be encouraged to make use of the list of IFCC Experts on the webpage. HM summarized the plan to collaborate with LIS vendors to address post analytical aspects and possibly attract new Corporate Members. A possible first step could be a meeting with LIS vendors for initial discussions. Leaders within IFCC will be identified to map out a project and plan.

3.2 Applications for Corporate Membership

2 new applications were received.

3.3 Resignation of Corporate Members

Sonic – Unilabs – Elga Veolia – Philips – Axis Shield – Instrumentation Lab

Annual Dues for Corporate Members

The status of outstanding membership dues was reviewed.

4.0 Affiliate Members

4.4 Annual Dues for Affiliate Memberships

The EB discussed options for addressing perceived inequalities in the dues for Affiliate Members. The development of a strategy to ensure fair and equitable dues for Affiliate Members has been included in the EB Strategic Plan. No change to the Affiliates dues structure will occur for 2018.

5.0 Regional Organisations

5.1 Asia-Pacific Federation of Clinical Biochemistry and Laboratory Medicine (APFCB)

A report was presented by SSE.

5.2 Latin-American Confederation of Clinical Biochemistry (COLABIOCLI)

A report was presented by RSA

RSA will ask the COLABIOCLI to consider a joint funding arrangement with IFCC for Radio EI Microscopio

5.4 European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

A report was presented by SSA

5.5 Arab Federation of Clinical Biology (AFCB)

A report was presented by AH.

5.6 African Federation of Clinical Chemistry (AFCC)

A report was presented by ABO

5.7 North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)

AG provided an oral report.

15.0 Financial Matters

TO raised a concern about increased expenses for member's travel and questioned the possible use of a travel agent to book all flights. It was decided to compare the actual flight expenses for the General Council compared to the estimated best fares and determine if there is a need to consider a travel agent or some other solution to manage travel costs.

15.1 Organization of Finances - Treasurer's Report

15.2 Budget

TO presented the draft budget for 2018 based upon functional unit requests and the previous year's actual expenses. Total revenue is estimated at 612,000 CHF, expenses at 1,712,107 CHF for a deficit of 1,100,107 CHF. The EB approved the budget with minor changes. TO will communicate the revised budget amounts to the Divisions.

15.3 Income and Expenditure

TO presented a report of the IFCC income and expenses for 2017, as well as current statement of investments and accounts. Total revenue was 2,027,641 CHF, expenses were 1,549,017 CHF for a profit of 478,624 CHF. Current accounts are 596,171.06 CHF, 5,258.02 USD and 460,099.19 Euro. Investments are 3,256,922 CHF

15.7 Financial Advisory Committee

It was agreed that the previous practice of the Financial Advisory Committee meeting to develop the budget prior to the February EB meeting was not feasible and will be removed from the Procedures Manual.

6.0 International and Professional Organisations

6.1 World Health Organisation (WHO)

This activity requires a lot of work but the EB feels that it is a worthwhile effort to maintain this important relationship.

6.13 World Association of Societies of Pathology and Laboratory Medicine (WASPaLM)

WASPaLM sponsored a symposium at WorldLab Durban and IFCC sponsored a symposium at the WASPaLM congress in Kyoto.

EB will investigate further congress activity with WASPaLM as is reasonable.

6.23.3 Forum for Inter-Organizational Cooperation in Metrology (FICOM)

It was noted that ISO TC 212 and its WG 2 on Reference Systems met in Brussels in December 2017. This meeting was attended by Neil Greenberg (Chair WG 2). The EB commended NG on the good job he has done.

6.31 European Commission - Joint Research Centre (JRC) (prev. European Institute for Reference Materials (IRMM))

HM reported that a document has been prepared on the history of reference material preparation and the JRC would like to publish this document. The EB supports this in principal and would like to review the article before final approval.

JRC will be named as a “key partner” on the IFCC website.

6.37 National Institute for Standards (NIST)

The IFCC has a long and positive relationship with NIST. Karen Phinney is the new NIST representative to the SD.

6.40 Other business:

The EB has received a request for collaboration with European Society for Clinical Cell Analysis (ESCCA). MF has met with the ESCCA President.

HM will ask the EMD to establish a joint collaboration with this group.

The Association for Molecular Pathology has inquired if the IFCC wants to have a booth at their meet. The IFCC will not have a booth but is open to other forms of collaboration and are awaiting a reply.

It was noted that these organizations are not the same as Affiliate Members in that they are usually international organizations that do not want to join the IFCC but wish to collaborate on some level. It was agreed that the category of International and Professional Organisations was appropriate.

7.0 Committee on Congresses and Conferences (C-CC)

7.1 Congresses and Conferences Executive Committee

The EB reviewed the report from C-CC and responded to the questions presented below.

The EB will work with C-CC to avoid conflict between WorldLab and EuroMedLab congresses in the same year. This matter will be addressed as we get closer to 2029, the next time this will occur.

7.2 International Congresses of Clinical Chemistry and Laboratory Medicine (ICCLM)

7.2.23 IFCC WorldLab Durban 2017

The EB reviewed the final outcome of WorldLab Durban 2017 and feels that the congress was a success, in terms of meeting its financial goals, in highlighting clinical chemistry in South Africa and in hosting approximately 450 delegates from Sub-Saharan Africa, many of whom were young scientists.

7.2.24 IFCC WorldLab 2020, Seoul (KR) Seoul, May 24-28, 2020

The EB confirmed HM as IFCC EB representative to the Congress Organizing Committee and received a report from HM that plans are underway with no problems.

7.2.25 IFCC WorldLab 2023, Rome (IT), May 21-25, 2023

The IFCC EB representative to the Congress Organizing Committee will be the President-Elect as determined in 2020.

7.3 IFCC Regional Congresses of Clinical Chemistry and Laboratory Medicine

7.3.1.15 Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine – APFCB 2019, Jaipur – Rajasthan (IN), 17-20 November 2019

SEE reported that the plans for the congress are underway and there are no problems.

7.3.2.22 EuroMedLab 2017, Athens (GR), June 11-15, 2017

The auditor's report for EuroMedLab 2017, Athens (GR) was received.

7.3.2.23 EuroMedLab 2019, Barcelona (ES), May 19-23, 2019

MF reported that the plans for the congress are well underway and corporate sponsorship has been very good.

7.3.2.24 EuroMedLab 2021, Munich (DE), May 16-20, 2021

HM, TO and someone from the C-CC will be the IFCC representatives to the Congress Organizing Committee.

Philippe Gillery will identify 3 members for the Scientific Program Committee.

7.3.4.24 Latin American Confederation of Clinical Biochemistry -COLABIOCLI Panama, September 10-13, 2019

RSA reported that the planning for the congress is underway with no problems.

Prof Raymondo notified the EB that the XXIII Latin American Congress of Clinical Biochemistry, held in Punta del Este, September 2017, was a success. The congress was organized by the Uruguayan Biochemical Association, with about 500 delegates.

7.3.6.15 Arab Federation of Clinical Biology - AFCB

AFCB Regional Congress, Palestine, April 18 – 21, 2018, IFCC is sponsoring 2 Symposia along with VLP support.

7.3.7.6 African Federation of Clinical Chemistry (AFCC) Congress

To be decided

7.4 IFCC Specialised Conferences

7.4.1.16 Roche Bergmeyer Conference, March 2018, Eibsee, Germany

Title: "Coagulation". RH reported that the Bergmeyer Conference is delayed by one year to 2019.

7.4.9 IFCC-Abbott Turning Science into Caring (TSIC)

Abbott is planning to hold 2 Turning Science into Caring events, one in Shanghai, China, 13th -14th July, 2018 and one in India 18-19 August, 2018. The IFCC has previously collaborated in these events according to an agreement.

7.5 Congresses Guidelines

The EB approves of the revised document "Guidance for National and International Congresses". The C-CC will draft an article for the CPD to help create awareness of the new important document.

"IFCC Guidelines for Compliance with Applicable Codes of Ethical Business Practice"

EB members should submit any questions concerns regarding the MedTech Europe Code and/or the EthicalMedTech Conference Vetting System to J. Wesenberg by not later than the end of February 2018.

The EB recognizes the serious problem of Predatory Congress Organizers and HM will consider possible articles or presentations to create awareness of this issue among our members including discussion at the General Conference 2018.

7.8.1 Congresses with IFCC Auspices

The list of congresses awarded IFCC auspices is updated and published on the IFCC website.

7.9.14 IFCC General Conference

This event is confirmed for Budapest (HU) on November 10th-11th, 2018 (Saturday-Sunday).

Functional units will hold closed meetings November 8th and 9th, according to the Chairs' planning.

PB has requested a reply from Chairs who plan to hold meetings by March 5, 2018.

7.20 Membership

The EB approved the appointments of one Full Member, one Corporate Member and three Corresponding Members, previously by email.

11.00 Emerging Technology Division (ETD)

Congratulations to the Chair and the Executive Committee for the good work and progress achieved with creation of this new Division.

11.1 ETD Executive Committee

The EB reviewed the report from the ETD and approved MF and Larry Kricka be added as consultants to the EC.

11.2 ETD Committees

The EB noted that with everyone starting at the same time, they need stagger the end of term for some members so all don't end at same time.

11.2.1 Committee for Advanced Paediatric Laboratory Medicine (C-APLM) (ex Task Force on Paediatric Laboratory Medicine -TF-PLM – 13.01.02)

The EB suggests that the ETD consider the objectives of the Committee for Advanced Paediatric Laboratory Medicine (C-APLM) and potential integration of work being done in this area by other international societies.

9.0 Education and Management Division (EMD)

9.1 Division Executive Committee

The EB previously accepted via email the nomination of Nader Rafai to the EC.

The EB reviewed the Strategic Plan from the EMD.

9.2 EMD Committees

A number of TFs have been converted to Committees within EMD. EMD has done a very good job to achieve this. There are a larger number of members on these committees as a result of the transition from TFs but it is expected that this will be reduced over time.

9.2.15 Committee on Proficiency Testing (ex Task Force on Proficiency Testing -TF-PT - 13.01.11)

The EB will ask for more information on the relationship between the TF-PT and the private provider regarding the new EQA project.

9.2.16 Committee on Value Proposition for Laboratory Medicine (C-VPLM)

The EB agreed that there should be cooperation between the C-VPLM and the EFLM Test Evaluation WG.

9.4 Special Projects

9.4.1 Visiting Lecturer Programme

The approved VLP applications were reviewed.

Abbott will continue to support the Visiting Lecturer Programme for 2018

8.0 Scientific Division (SD)

8.1 SD Executive Committee

The Minutes of the 60th SD Executive Committee meeting held in Durban, October 2017 were received.

The EB discussed the recommendations from the SD Executive Committee.

The EB confirms that nominations for IFCC positions must come from the National Society where the individual is a member in good standing.

8.2 SD Committees

8.2.6 Nomenclature, Properties and Units (C-NPU)

The EB approved the appointment of K. Toska as Chair and Eline Van der Hagen as a new member.

8.2.11 Molecular Diagnostics (C-MD)

The EB approved the recommendations regarding membership, terms of references and projects as proposed by the SD EC.

8.2.23 Traceability in Laboratory Medicine (C-TLM)

The EB approved the appointment of A. Kessler as the new Chair.

The EB approved the addition of a young scientist as a corresponding member.

8.2.25 Standardisation of Thyroid Function Tests (WG-STFT)

The EB approved the appointment of H. Vesper as the new Chair.

The EB approved the addition of a member from a developing country as a corresponding member.

8.13 Joint Committee for Traceability in Laboratory Medicine (JCTLM)

The EB will consider the appointment of a new Chair at the July EB meeting.

8.16 International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR) (formerly 6.38)

Congratulations to the Office, Graham Beastall, Gary Myers and MF for work done to take responsibility for administration. EB approves that IFCC will be a council member at 10,000 USD fee.

10.0 Communications and Publications Division (CPD)

10.1 CPD Executive Committee

K. Adeli will be completing his term as Chair this year. DK will discuss options with KA and the EB will consider options for a new Chair at the July EB meeting.

10.2 CPD Committees

10.2.1 Committee for Public Relations (C-PR)

TO reported that Abbott has stopped financial support for Labs are Vital, which had been announced some years previously as it was transformed into an independent body.

10.2.2 Committee on Internet and Distance Learning (C-IDL)

It was noted that this is now a joint Committee with EMD

10.6 Publications

The EB confirmed that the abstracts for EuroMedLab congresses should be published alternately between CCA and CCLM and noted that WorldLab abstracts should only be published by CCA under the current agreement.

The EB feels that the existing IFCC strategic plan objective already cover lay public, healthcare administrators and decision makers and there is no need to list them specifically.

10.9.2 IFCC Booth

The IFCC will have a booth at the AACC 2018 Chicago congress

12.0 IFCC Awards (prev. numbering 11)

12.1 Awards Committee

The Chair of the Awards Committee will be the Past President, and the Chair, with input and approval from the EB, will select other members.

IFCC awards are 10,000 euros (5,000 to recipient and 5,000 toward expenses). There are currently 2 awards without Corporate sponsors.

Special Projects and Task Forces

13.1.01 Task Force on Ethics (TF-Ethics)

EB appointed Nilda Fink as the new Chair and AG will be the EB Liaison.

13.1.06 Task Force for Young Scientists (TF-YS)

It was noted that there were some issues with coordination of YS events with other activities at the Durban congress. TO will be the EB Liaison.

13.1.12 Special Project on History

At the next EB meeting in Rome the EB will consider opening a call for an officer interested in working with PW to continue this project together. The call will be made considering the activity planned by PW.

13.2 Professional Exchange Programmes

The report on PSEP and PMEP applications was reviewed.

13.3 Roche Travel Scholarships

Approval of Roche 2018 funding was noted.

The EB approved use of the Roche scholarships for young scientists to attend the Rome Mediterranean conference, and preferably awarded to young scientists from Mediterranean countries, as is in compliance with the Roche TORs (recipients less than 40 years and from developing countries).

16.0 Organisational Matters

16.4 Annual Report

The Annual Report 2017 is in preparation

16.5 Handbook

The Handbook for 2018-2020 is in preparation.

16.6 Procedures Manual

DK, HM and MF are working on updates to the Procedures Manual.

16.8 Numbering System

The IFCC Numbering System is a valuable tool for organization of IFCC business. ETD has been numbered as 11.00 and Awards renumbered as 12.00.

16.40 Other business

Mauro Zaniboni provided an update on the implications for the IFCC Head Office as a result of the EU General Data Protection Regulation. The impact on the IFCC will be minor as we collect a minimum of personal information. MZ will put in place the required processes.

PB will take the training as a Trusted Partner for the MedTech Europe Ethical Code.

19.0 Meetings

19.1 Council Meetings

19.1.23 Durban, 2017

19.1.24 Seoul, 2020

19.6 General Conference

19.6.14 Budapest, 2018

The General Conference will be held on Saturday and Sunday, Nov 10 and 11, 2018 at the Novotel, Budapest City Hotel and Congress Center. 250 delegates are expected.

The EB Secretary, DK, is responsible for the organization of the GC. MF will contact Ioana Brudasca to serve a co-Chair. The experience from the last GC will be considered in planning the Budapest GC. A "check in" process linked to delegate name tags will be implemented to monitor delegate participation. PB has contacted the functional group Chairs regarding holding their committee meetings at the GC and replies are expected by March 5.

19.80 Executive Board Meetings

Milano, Saturday, Sunday and Monday, February 17-19, 2018

Rome, Thursday and Friday, 5-6 July 2018

General Conference, Budapest (HU), Thursday and Friday, November 8-9, 2018